Prediction of efficacy and tolerability of antidepressants and mood stabilizers

Prediction of efficacy and tolerability of antidepressants and mood stabilizers

Antidepressants and mood stabilizers are drugs for the treatment of psychiatric disorders such as depression and bipolar disorder. Psychiatrists aim to recommend an optimal drug depending on the individual symptoms and risk of adverse events. The drug would ideally improve the symptoms with a low risk of adverse events.Individualized prediction of the response to a drug and the occurrence of adverse events could improve psychiatric treatment but the identification of predictors is not well-established and remains a challenge. Machine learning techniques are statistical models that could help to identify these predictors. We aim to identify predictors, which are associated with a better treatment response and lower risk of adverse events. To this end, we will assess predictors in a comprehensive dataset of drug trials of antidepressants and mood stabilizers in affective disorders with machine learning techniques.

[{ "PostingID": 53, "Title": "GSK-LBI108884", "Description": "An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder" },{ "PostingID": 55, "Title": "GSK-SCA104779", "Description": "Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients" },{ "PostingID": 56, "Title": "GSK-SCA106052", "Description": "Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))" },{ "PostingID": 82, "Title": "GSK-PIR112487", "Description": "A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study>" },{ "PostingID": 1280, "Title": "GSK-BRL-029060/329: Acute Phase", "Description": "A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase" },{ "PostingID": 1617, "Title": "GSK-29060/785", "Description": "A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety" },{ "PostingID": 1623, "Title": "GSK-MY-1043/BRL-029060/115", "Description": "A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder." },{ "PostingID": 1632, "Title": "GSK-BRL-029060/377", "Description": "A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression." },{ "PostingID": 1633, "Title": "GSK-29060/448", "Description": "A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression" },{ "PostingID": 1634, "Title": "GSK-29060/449", "Description": "A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression" },{ "PostingID": 1637, "Title": "GSK-BRL-029060/701", "Description": "A multi-center, double blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Paroxetine in children with major depression." },{ "PostingID": 1638, "Title": "GSK-29060/810", "Description": "A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression." },{ "PostingID": 1639, "Title": "GSK-29060/874", "Description": "Assessment of Paxil CR, 12.5 and 25 mg/day in treating elderly patients with major depression" },{ "PostingID": 1806, "Title": "GSK-SCA100223", "Description": "A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder" },{ "PostingID": 1807, "Title": "GSK-SCA30924", "Description": "Double blind placebo controlled study of lamictal in acute bipolar depression" },{ "PostingID": 1811, "Title": "GSK-SCAB2003 (105-605)", "Description": "A Multicenter, Double-blind, Placebo-controlled, Randomized, Fixed-dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Subjects with Bipolar I Disorder" },{ "PostingID": 1821, "Title": "GSK-SCA40917", "Description": "Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness." },{ "PostingID": 1826, "Title": "GSK-SCA40910", "Description": "A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety, Efficacy, and Tolerability of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder" },{ "PostingID": 1982, "Title": "GSK-NKF100096", "Description": "A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD)" },{ "PostingID": 2063, "Title": "GSK-AK130939", "Description": "A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder." },{ "PostingID": 2064, "Title": "GSK-WXL101497", "Description": "A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder." },{ "PostingID": 2067, "Title": "GSK-WELL ZYB40021", "Description": "A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension" },{ "PostingID": 2122, "Title": "GSK-29060/01/001", "Description": "A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients" },{ "PostingID": 2123, "Title": "GSK-29060/02/001", "Description": "A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients" },{ "PostingID": 2124, "Title": "GSK-29060/03/001", "Description": "A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients" },{ "PostingID": 2125, "Title": "GSK-29060/07/001", "Description": "A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia" },{ "PostingID": 2126, "Title": "GSK-29060/009", "Description": "A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine" },{ "PostingID": 2127, "Title": "GSK-29060/057", "Description": "A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression" },{ "PostingID": 2128, "Title": "GSK-29060/106", "Description": "A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD)" },{ "PostingID": 2129, "Title": "GSK-29060/128", "Description": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder" },{ "PostingID": 2130, "Title": "GSK-29060/251", "Description": "A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety" },{ "PostingID": 2132, "Title": "GSK-26090/007", "Description": "A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression" },{ "PostingID": 2133, "Title": "GSK-29060/276", "Description": "A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo" },{ "PostingID": 2134, "Title": "GSK-29060/012_3", "Description": "A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin" },{ "PostingID": 2135, "Title": "GSK-29060/282", "Description": "A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design" },{ "PostingID": 2136, "Title": "GSK-29060/327", "Description": "A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia." },{ "PostingID": 2137, "Title": "GSK-29060/487", "Description": "A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients" },{ "PostingID": 2138, "Title": "GSK-29060/625", "Description": "A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression." },{ "PostingID": 2139, "Title": "GSK-29060/329_1", "Description": "A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Continuation Phase." },{ "PostingID": 3149, "Title": "GSK-BRL-029060/715", "Description": "A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression" },{ "PostingID": 3151, "Title": "GSK-BRL-029060/716", "Description": "A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD)" },{ "PostingID": 3156, "Title": "GSK-PCR111656", "Description": "An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga" },{ "PostingID": 3161, "Title": "GSK-NKD20006", "Description": "An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder" },{ "PostingID": 3344, "Title": "GSK-29060/653 (BRL-029060/653)", "Description": "A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet" },{ "PostingID": 3563, "Title": "GSK-HTP109035", "Description": "A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder" },{ "PostingID": 3705, "Title": "GSK-AK1113351", "Description": "Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study" },{ "PostingID": 3786, "Title": "GSK-SNV111914", "Description": "A Single-Blind, Randomised, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK1360707" },{ "PostingID": 3790, "Title": "GSK-SCA102833", "Description": "The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age" },{ "PostingID": 4238, "Title": "GSK-PCR112810", "Description": "A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder" },{ "PostingID": 4424, "Title": "GSK-PKI113009", "Description": "A six week randomized, double-blind, multi-center, placebo-controlled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder" },{ "PostingID": 4738, "Title": "GSK-PKI108574", "Description": "A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period" },{ "PostingID": 4919, "Title": "GSK-29060/274", "Description": "A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo" },{ "PostingID": 16074, "Title": "GSK-SCAA2010", "Description": "A Multicenter, Double–Blind, Placebo–Controlled, Flexible Dose (100–400mg) 10 Week Evaluation Of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Bipolar Disorder" },{ "PostingID": 16075, "Title": "GSK-SCAB2001", "Description": "A Multicenter, Double–Blind, Placebo–Controlled, Fixed Dose (50 or 200mg per day) 7 Week Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar Disorder" },{ "PostingID": 20065, "Title": "GSK-PAR 29060.308 (HP/81/74A)", "Description": "Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily" },{ "PostingID": 20066, "Title": "GSK-PAR 29060.309 HP/81/162A", "Description": "Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily" },{ "PostingID": 20067, "Title": "GSK-PAR 29060.310 (HP 81/85A)", "Description": "Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily" },{ "PostingID": 20068, "Title": "GSK-PAR 29060.316 (HP/82/47A)", "Description": "Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily" },{ "PostingID": 20069, "Title": "GSK-PAR 29060.314 (HP 82/134)", "Description": "Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients" },{ "PostingID": 20070, "Title": "GSK-PAR 29060/281", "Description": "A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice" },{ "PostingID": 20071, "Title": "GSK-PAR 290 MDF 29060 1727 M", "Description": "A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly" },{ "PostingID": 20072, "Title": "GSK-PAR MDED/29060/III/86/1728M291", "Description": "A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients." },{ "PostingID": 20073, "Title": "GSK-MDF/29060/III/070/88/MC", "Description": "A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age >60 years) with moderate depression according to feighner's criteria" },{ "PostingID": 20074, "Title": "GSK-MY-1001/BRL-029060/1/CPMS 069", "Description": "A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients." },{ "PostingID": 20075, "Title": "GSK-MY-060/BRL-029060/1.", "Description": "A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression." },{ "PostingID": 20076, "Title": "GSK-MY 1021/BRL 029060/1/CPMS/061", "Description": "A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression" },{ "PostingID": 20077, "Title": "GSK-PAR 29060/078", "Description": "A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mg Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder" },{ "PostingID": 20078, "Title": "GSK-29060/063", "Description": "A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression." },{ "PostingID": 20079, "Title": "GSK-MY-1005/BRL-029060/1/CPMS-112", "Description": "A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients" },{ "PostingID": 20080, "Title": "GSK-29060/064", "Description": "A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients" },{ "PostingID": 20081, "Title": "GSK-MY-1010/BRL029060/1/CPMS 079", "Description": "A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients" },{ "PostingID": 20082, "Title": "GSK-MY-059.073/29060/1", "Description": "A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression" },{ "PostingID": 20083, "Title": "GSK-MY-1055/BRL-029060/1/CPMS-245 PAR 245", "Description": "A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety" },{ "PostingID": 20084, "Title": "GSK-29060/131", "Description": "A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect" },{ "PostingID": 20085, "Title": "GSK-MY-1008/BRL-029060/2/CPMS-076", "Description": "The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients" },{ "PostingID": 20087, "Title": "GSK-89", "Description": "Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients" },{ "PostingID": 20088, "Title": "GSK-WELL 203", "Description": "A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients" },{ "PostingID": 20089, "Title": "GSK-Well 209", "Description": "The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients" },{ "PostingID": 20090, "Title": "GSK-WELL 212", "Description": "A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients" },{ "PostingID": 20091, "Title": "GSK-WELL AK1A4002", "Description": "A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression" },{ "PostingID": 20092, "Title": "GSK-WELL AK1A4001", "Description": "A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression" },{ "PostingID": 20093, "Title": "GSK-WELL AK1A4007", "Description": "A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression" },{ "PostingID": 20094, "Title": "GSK-WELL 205", "Description": "A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients" },{ "PostingID": 20095, "Title": "GSK-WELL AK1A4006", "Description": "A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression" },{ "PostingID": 20102, "Title": "GSK-LOC114589", "Description": "A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (bupropion XL 300mg once daily), Escitalopram oxalate (escitalopram, 10mg-20mg once daily) in Subjects with Major Depressive Disorder" },{ "PostingID": 20175, "Title": "GSK-WELL AK140016", "Description": "An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder" },{ "PostingID": 20792, "Title": "GSK-PAR MDSA/29060/III/86/03 (019)", "Description": "Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients" },{ "PostingID": 20793, "Title": "GSK-MDUK/29060/III/85/028A (PAR 184)", "Description": "An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic" },{ "PostingID": 20794, "Title": "GSK-PAR MDUK 032", "Description": "A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients" },{ "PostingID": 20795, "Title": "GSK-MDUK/29060/III/85/043", "Description": "An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study)." },{ "PostingID": 20796, "Title": "GSK-PAR – MDUK/29060/III/87/049 Hutchinson", "Description": "A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline" },{ "PostingID": 20797, "Title": "GSK-29060/074", "Description": "Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression" },{ "PostingID": 20798, "Title": "GSK-PN-MDHU-29060-III-1 (29060/077)", "Description": "Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression" },{ "PostingID": 20799, "Title": "GSK-6121 RAD/Paroxetine/C/4 (PAR 260)", "Description": "Paroxetine in the treatment of depression – a randomised comparison with amitriptyline." },{ "PostingID": 20800, "Title": "GSK-PAR 029060.292", "Description": "A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline" },{ "PostingID": 20801, "Title": "GSK-PAR 29060.318 (HP/82/64A)", "Description": "Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily" },{ "PostingID": 20804, "Title": "GSK-BRL-29060/109", "Description": "A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent." }]